These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 23345613)

  • 1. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
    Hwang IC; Bruera E; Park SM
    Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE; Xie F; Messina J; Segal TJ
    J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent development in therapeutics for breakthrough pain.
    Davis MP
    Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
    Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
    J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
    Fine PG; Narayana A; Passik SD
    Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
    Shinjo T; Okada M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
    Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
    Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.